Rosacea is a common inflammatory condition that typically manifests with pale skin and light eyes. The reported prevalence of Rosacea is between 0.5% and 10%.
Generally, Rosacea is expressed as flushing in patients in their 20s, which becomes bothersome to patients in their 30s, and may persist to advance thereafter. Rosacea occurring in the fourth and fifth decades of life is associated with morbidity.
Rosacea also affects children but generally remains unnoticed as the tendency of flushing and erythema is mistaken as “healthy glow” in children. There are chances that in paediatric patients having a family history of Rosacea, the disorder may exist and advance into adulthood. 
Subtype 1: Facial redness, flushing and visible blood vessels
Subtype 2: Acne-like breakouts
Subtype 3: Thickening skin
This subtype is uncommon. When this subtype occurs, the patient usually initially presents with signs and symptoms of another subtype of rosacea.
Signs of this subtype are:
Subtype 4: In the eyes
People with rosacea in their eyes may suffer from the following symptoms:
The exact causative factor for rosacea is not known, though several probable factors have been identified. There are chances that a combination of these factors may give rise to rosacea but there is no sufficient data to confirm this conclusion.
The below mentioned triggers are not direct causes of rosacea but these may worsen symptoms in several people suffering from rosacea. The type of trigger differs from person to person.
Few triggers that have been commonly noticed are:
Modern medical treatment plan for rosacea aims at decreasing the intensity and number of inflammatory lesions and at reducing erythema with the help of both systemic and topical agents.
1) Oral agents
The only oral agent approved by the FDA for the treatment of rosacea is anti-inflammatory dose doxycycline (40-mg delayed-release capsule prescribed once in a day).
Based on prevalent case reports, studies and clinical experiences, a number of oral antibiotics have been used off-label in the treatment of rosacea.
2) Topical agents
Selection of topical agents for the treatment of rosacea is dependent on several criteria namely:
Three topical therapies approved by the Food and Drug Administration (FDA) for rosacea are:
Rosacea is effectively treated with the help of topical metronidazole and systemic antibiotics having anti-inflammatory activity. In cases of mild-to-moderate rosacea, an anti-inflammatory dose of doxycycline along with topical metronidazole gel 1% seems to be beneficial in decreasing the number of inflammatory lesions and is well accepted.
Quite a few reports have established light-based treatments to be beneficial in the management of erythema observed in rosacea patients. Intense pulsed light (IPL) at a wavelength of 550 to 670 nm may be helpful for treating rosacea.
Doctors usually advise patients suffering with rosacea to:-
Non-medical therapies offer noteworthy benefits. They help in improving the roughness, dryness and desquamation of the skin. They also help reduce considerably the sensitivity of the skin and therefore improve skin comfort. 
 Rosacea: A Review. 2015. Rosacea: A Review. [ONLINE] Available at: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2700634/. [Accessed 29 October 2015].
 Rosacea: Signs and symptoms. [ONLINE] Available at: https://www.aad.org/dermatology-a-to-z/diseases-and-treatments/q---t/rosacea/signs-symptoms. [Accessed 29 October 2015].
 Rosacea - Causes - NHS Choices. 2015. Rosacea - Causes - NHS Choices. [ONLINE] Available at: http://www.nhs.uk/Conditions/Rosacea/Pages/Causes.aspx. [Accessed 29 October 2015].
 Comprehensive Medical Management of Rosacea. [ONLINE] Available at: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2989804/. [Accessed 29 October 2015].